Article
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
The Lancet. Oncology - 1 Sept 2016
Villani Anita, Shore Ari, Wasserman Jonathan D, Stephens Derek, Kim Raymond H, Druker Harriet, Gallinger Bailey, Naumer Anne, Kohlmann Wendy, Novokmet Ana, Tabori Uri, Tijerin Marta, Greer Mary-Louise C, Finlay Jonathan L, Schiffman Joshua D, Malkin David
Abstract excerpt
BACKGROUND: Carriers of a germline TP53 pathogenic variant have a substantial lifetime risk of developing cancer. In 2011, we did a prospective observational study of members of families who chose to either undergo a comprehensive surveillance protocol for individuals with Li-Fraumeni syndrome or not. We sought to update our assessment of and modify the surveillance protocol, so in this study we report both...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.